ライフサイエンスコーパス: cell count

1 d antiretroviral therapy irrespective of CD4 cell count.

2 ion, even in patients with a low endothelial cell count.

3 ere quantitatively assayed for phytoplankton cell count.

4 logical failure, and mean differences in CD4 cell count.

5 y lactation and in samples with high somatic cell count.

6 dle-income region, HIV RNA, and baseline CD8 cell count.

7 ections in HIV-positive people with high CD4 cell count.

8 mal blood cells, or reduced peripheral blood cell count.

9 recommend initiating ART regardless of CD4+ cell count.

10 infected with HIV irrespective of their CD4 cell count.

11 lantation and have a low corneal endothelial cell count.

12 were independent of current and nadir CD4+ T-cell counts.

13 reated HIV coinfection with preserved CD4+ T-cell counts.

14 e T-cell clones correlated with respective T-cell counts.

15 nt suitability, or reductions in endothelial cell counts.

16 r antagonist protein, inhibited BAL TH2/TH17 cell counts.

17 ergen-specific Treg cell and activating mast cell counts.

18 ex, technical covariates, and complete blood cell counts.

19 ns, such as opportunistic infections and CD4 cell counts.

20 epressant use, inflammatory status and blood cell counts.

21 tively correlated with increased CD8(+) PB T-cell counts.

22 vels were correlated with increases in CD4 T-cell counts.

23 inophil counts and not associated with CD4 T-cell counts.

24 -8.1 to 23.6; P = .34) did not exhibit lower cell counts.

25 who were mechanically ventilated had reduced cell counts.

26 nivariable analysis, higher time-updated CD4 cell count (0.78, 0.71-0.85, p=0.0001) was associated wi

27 viability (AUC-ROC for ATP=0.78; AUC-ROC for cell count=0.88), the combination of HO-1 and cell count

28 e were no significant changes in endothelial cell count 1 year after treatment.

29 Optimal thresholds for white blood cell count (11600/microL), absolute neutrophil count (41

30 The CSF cell count, 14-3-3 protein detection and S100B were of l

31 ), anaemia (26 [29%]), decreased white blood cell count (17 [19%]), and decreased lymphocyte count (1

32 as 321 cells per muL higher, and average CD4 cell count 194 cells per muL higher than the deferred-in

33 openia (27 [10%]), and decreased white blood cell count (21 [8%]).

34 agnostic algorithm (58.5% female; median CD4 cell count, 278/muL; WHO HIV stage I, 66.8%), 98 (10.1%)

35 esponders at 28 weeks had higher median Treg cell counts 3 months post-ECP than nonresponders, as did

36 participants were enrolled (median CD4(+) T-cell count, 34 cells/microL).

37 randomly assigned (1:1) to point-of-care CD4 cell counts (366 compounds with 417 participants) or sta

38 10%] vs 41 [13%]), and decreased white blood cell count (39 [13%] vs 33 [11%]).

39 lasma viremia of <200 copies/mL (mean CD4(+)-cell count, 475.1+/-307.9 cells/muL).

40 ics included age 36 years (IQR 30-44), CD4 T-cell count 648 per muL (583-767), and HIV plasma viral l

41 .8] vs 4.5 [3.7-5.5] mg/dL), and white blood cell count (7000 [5900-8200] vs 6600 [5600-7800] cells/m

42 s included higher nadir and current CD4(+) T-cell counts, a plasma HIV-1 RNA level of >/= 1 copy/mL,

43 We tested the accuracy of the white blood cell count, absolute neutrophil count, and platelet coun

44 d infections were also observed at lower CD4 cell counts after adjusting for age.

45 d in patients who do not regain normal CD4 T cell counts after virologically successful antiretrovira

46 Moreover, we developed an automatic cell counting algorithm to quantify the number of detect

47 White blood cell count analysis after alpha-radioimmunotherapy indic

48 95% CI 0.70-0.99; I(2)=51%, adjusted for CD4 cell count and ART duration), and there was some evidenc

49 egression, adjusting for demographics, blood cell count and distribution, and another metric with a d

50 lue of several laboratory tests (white blood cell count and hepatic and lipid panels), yet (2) the me

51 differ in the threshold used to measure CD4 cell count and HIV RNA viral load every 3-6 months (when

52 hip ratio, alanine transaminase, white blood cell count and lower high-density lipoprotein cholestero

53 ination revealed mildly elevated white blood cell count and protein levels.

54 IL-4, TSLP, IL-17A, EPO activity, total cell count and specific IgE and IgG1 levels were lower i

55 Factors associated with higher CD4 cell count and viral load (VL) suppression<400 c/mL amon

56 wth as judged by phosphohistone H3 staining, cell counting and cleaved caspase-3 levels.

57 eration by using 5-bromo-2'-deoxyuridine and cell counting and in the expression of p21, BCL2-associa

58 Regulatory T cell counts and % varied greatly among cGvHD patients, a

59 s associated with a higher increase in CD4 T cell counts and a decreasing trend in CD8 T cell counts

60 nation of large olfactory bulbs, high mitral cell counts and a greatly enlarged nasal cavity likely r

61 known about the dynamics of mucosal CD8(+) T cell counts and activation of these cells during the cou

62 ction with a spectrum of peripheral CD4(+) T-cell counts and ART statuses.

63 is laboratory evaluation showed normal blood cell counts and comprehensive metabolic panel with a cal

64 ed elite controllers (ECs) maintain CD4(+) T cell counts and control viral replication in the absence

65 to analyze associations between pre-ART CD4+ cell counts and death, attrition, and death or attrition

66 also influenced by platelet and white blood cell counts and estroprogestogen intake.

67 of mTORC1 significantly increased red blood cell counts and hemoglobin content in the blood, improve

68 ulosis diagnosed had significantly lower CD4 cell counts and hemoglobin levels, more advanced WHO sta

69 cancer and determined by differences in CD4 cell counts and human immunodeficiency virus (HIV) RNA b

70 Circulating blood cell counts and indices are important indicators of hema

71 AT-RvD1-treated mice had lower total cell counts and neutrophils in bronchoalveolar lavage fl

72 levels were inversely correlated with CD8 T-cell counts and positively correlated with eosinophil co

73 ressing pDCs correlated inversely with CD4 T cell counts and positively with HIV viral loads.

74 luated the association between phytoplankton cell counts and subsequent illness among recreational be

75 patients correlated with circulating CD8+ T cell counts and was normalized in these patients followi

76 MICS baseline visit data with complete blood cell counts and, in a subset, acceptable sputum counts.

77 atients with FLT3-ITD, only age, white blood cell count, and < 4-log reduction in PB-MRD, but not FLT

78 id not develop, matched by age, sex, and CD4 cell count, and 37 unmatched HIV-infected patients with

79 refraction spherical equivalent, endothelial cell count, and adverse events.

80 ncluded younger age, higher initial CD4(+) T-cell count, and complete adherence to antiretroviral the

81 y analysis included body weight, white blood cell count, and hematocrit.

82 ood cell transfusion dependency, white blood cell count, and marrow blasts retained independent progn

83 eatinine clearance, haemoglobin, white-blood-cell count, and previous spontaneous bleeding) showed a

84 ection, DNA synthesis, apoptosis, migration, cell count, and protein activity assays were performed i

85 rates stratified by person-time in age, CD4 cell count, and VL and ARV categories.

86 mortality among PHIVY stratified by age, CD4 cell count, and VL and ARV status.

87 without HIV, 89 and 88 with HIV and high CD4 cell counts, and 91 and 91 with HIV and low CD4 cell cou

88 (ART) correlated with HIV viremia, CD4(+) T-cell counts, and immune activation markers, suggesting t

89 e), hepatobiliary enzyme levels, white blood cell counts, and iron homeostasis.

90 ReFACTor does not require knowledge of cell counts, and it provides improved estimates of cell

91 e CD4(+) and CD8(+) T cell counts, but not B cell counts, and preferentially increased CCR6(+) subset

92 sent with severely reduced switched memory B-cell counts, and some display an increase of CD21(low) B

93 b decreased airway hyperresponsiveness, mast-cell counts, and tryptase release.

94 S, HIV transmission category, nadir CD4(+) T-cell count, antiretroviral therapy, HIV RNA, liver fibro

95 visual field sensitivity to retinal ganglion cell count are discussed.

96 ology in high throughput, but only the final cell counts are commonly used for clinical decisions.

97 y ART initiation and maintenance of high CD4 cell counts are essential to further reducing KS inciden

98 Raised white blood cell counts as well as peaks of serum levels of C-reacti

99 erial infections, and mortality at lower CD4 cell counts, as expected.

100 fied by plasma HIV-1 RNA viral loads and CD4 cell count at baseline.

101 Increases in CD4(+) T-cell count at diagnosis and ART initiation suggest that

102 Trends in CD4(+) T-cell count at human immunodeficiency virus (HIV) infecti

103 ry, cardiac, and liver function, white blood cell count at least 3 x 10(9) cells per L, platelet coun

104 udy suggest that HIV patients with high CD4+ cell counts at the time of ART initiation may be at grea

105 count or re-present with persistent low CD4 cell counts because of poor adherence, resistance to ant

106 andan participants had absolute monoclonal B-cell count below one cell per muL, whereas the 21 UK par

107 Scheimpflug tomographies, endothelium cell count, best spectacle-corrected visual acuity (BSCV

108 well as differences in absolute monoclonal B-cell count between the two cohorts.

109 polymorphism correlated with CSF mononuclear cell count but not with mortality (P = .915).

110 rmal, the other two had elevated white blood cell count, but all of them had elevated CRP.

111 ly explained by ART-induced increases in CD4 cell count, but not by increases in neutrophil count.

112 lpha4beta7 increased the CD4(+) and CD8(+) T cell counts, but not B cell counts, and preferentially i

113 ed to epigenetic age and late differentiated cell counts, but was related to a decline in naive T cel

114 ve concentration range needed for downstream cell counting by pinwheel assay.

115 ysical triggers, BAT results, complete blood cell count, C-reactive protein levels, thyroid-stimulati

116 Point-of-care CD4 cell counts can improve linkage to HIV care among people

117 nd cumulative exposures (CD4 cell count, CD8 cell count, CD4/CD8 ratio, HIV RNA, and bacterial pneumo

118 updated lagged and cumulative exposures (CD4 cell count, CD8 cell count, CD4/CD8 ratio, HIV RNA, and

119 Colony-forming unit numbers, host myeloid cell counts, cell recruitment, cytokine production, and

120 achieved extra 1.5-log reduction in sessile cell count compared with the 80 ppm CIP alone treatment.

121 esponded with a greater decrease in leukemic cell count compared with those samples expressing a low

122 and some display an increase of CD21(low) B-cell counts (CVID 21low), whereas others do not (CVID 21

123 Airway mast-cell counts declined in both groups.

124 TGF-beta1(+) cell counts decreased in responders at the first biopsy,

125 either immediately, or deferred until CD4 T-cell counts decreased to 350 per muL or AIDS developed.

126 2.2; P = .18) and severe diabetes (mean [SD] cell count difference, 7.7 [8.1] cells/mm2; 95% CI, -8.1

127 Donors with diabetes (mean [SD] cell count difference, 9.0 [6.7] cells/mm2; 95% CI, -4.1

128 73) for threshold 350, and 24 month mean CD4 cell count differences were 0.4 (-25.5 to 26.3) cells pe

129 re (318 compounds with 353 participants) CD4 cell counts done at one of three referral laboratories s

130 cell counts and a decreasing trend in CD8 T cell counts during follow-up.

131 rge cohort of APL patients, high white blood cell count emerged as an independent predictor of early

132 -)-2 was able to significantly reduce viable cells count, endothelial cell migration, and tube format

133 but statistically significant improvement of cell-count estimates in whole blood as well as in mixtur

134 arrow samples, the microfluidic-based plasma cell counts exhibited excellent correlation with flow cy

135 CD4 cell counts fell to <200 cells/microL in 5.7% of monoinf

136 CD4 cell counts fell to <200 cells/microL in 7.4% patients,

137 A repeat cycle was administered when CD4 T-cell counts fell to <550 cells/microL.

138 Cell counts, flow cytometry, and next-generation sequenc

139 Here we report full cell counts for 15 gene-targeted strains of the OR-IRES-

140 ntitative PCR (qPCR) measurements as well as cell counts for BioBall reference standard and 24 enviro

141 rter LTL was associated with a lower CD34(+) cell count: for each 10% shorter LTL, CD34(+) levels wer

142 According to induced sputum cell count, four different asthma phenotypes have been r

143 Total cell counts from one male and one female retina revealed

144 ell count=0.88), the combination of HO-1 and cell count further improved the predictive ability (AUC-

145 Conclusions and Relevance: White blood cell count greater than 20000 cells/microL and total bil

146 13 x 10(9)/L) and proliferative (white blood cell count >/=13 x 10(9)/L) CMML.

147 9 per liter, multiply by 0.001); white blood cell count >/=15000/microL, 27% (95% CI, 18% to 36%); ab

148 nt >63% of their follow-up time with a CD4 T-cell count >500 cells/microL.

149 At the time of PCP, all patients had CD4 T-cell count >500/muL (median, 966/muL) and immunoglobulin

150 Comparing patients with current CD4 cell counts >/=700 cells/microL with those whose counts

151 venteen patients (42.5%) had CSF white blood cell counts >20/muL (mean, 57/muL), and 27 (67.5%) had h

152 rs ((LTNP-C), defined by maintaining CD4(+)T-cells counts >500 cells/mm(3) for more than 7 years afte

153 rs ((LTNP-C), defined by maintaining CD4(+)T-cells counts >500 cells/mm(3) for more than 7 years afte

154 1) added to high-risk patients (white blood cell count, >10 x 10(9)/L), as well as low-risk patients

155 Adjusting for CD4 cell counts had no effect on decay estimates.

156 bacterial infections in people with high CD4 cell counts have not been well described.

157 r age, sex, ethnicity, alcohol use, CD4(+) T-cell count, HCV genotype, gamma-glutamyl transferase lev

158 ome (CSF culture positivity, CSF white blood cell count, hemoglobin, Glasgow Coma Scale, and pulse ra

159 Combined with cell counts, heterogeneous gene expression may provide d

160 ricuspid regurgitation velocity, white blood cell count, history of acute chest syndrome, and hemoglo

161 l parameters, including body mass index, CD4 cell count, HIV load, and C-reactive protein levels were

162 were well-balanced with respect to age, CD4 cell count, HIV RNA load, and antiretroviral treatment.

163 -7 increases total circulating CD4 and CD8 T cell counts; however, its effect on HIV-specific CD8 T c

164 tly higher in patients with high white blood cell count (HR 2.45, p 0.011), raised serum alanine amin

165 Higher baseline log10 CD4+ cell count (HR, 0.50; 95% CI, .40-.63) and increasing ag

166 rd ratio [HR], 3.299; P < .001), white blood cell count (HR, 1.910; P = .017), platelet count (HR, 7.

167 ght ventricular hypertrophy index, and total cell count in BALF.

168 ion at 8 hours, reflected by increased white cell count in both sexes.

169 in men, and with higher BMI and white blood cell count in women (differences 0.03-0.06 standard devi

170 bacterial infection in people with high CD4 cell counts in a preplanned analysis of the START trial.

171 INTERPRETATION: Point-of-care CD4 cell counts in a resource-limited HBCT setting doubled l

172 orized into the four phenotypes according to cell counts in induced sputum.

173 mean airway wall thickness and inflammatory cell counts in lungs from patients with COPD compared wi

174 Since the reduced number of CD4(+) T cell counts in patients' peripheral blood corresponds to

175 This was associated with higher DC and T-cell counts in pericardial AT, which outnumbered DCs and

176 undetectable viral loads and normal CD4(+) T cell counts in plasma and gastrointestinal tissues for m

177 All other blood cell counts in Tpm4-deficient mice were normal.

178 itoring strategies based on time-varying CD4 cell counts in virologically suppressed HIV-positive ind

179 From 2006 to 2012, the median CD4(+) T-cell count increased from 325 to 379 cells/microL at dia

180 on, n=1 each; placebo: vomiting, white blood cell count increased, n=1 each).

181 n seronegative acute HIV infection, CD8(+) T cell counts increased in the epithelium, but not in the

182 regimen, and calendar year, low current CD4 cell counts increased the risk of developing KS througho

183 topic ERG, visual evoked potentials, IHC and cell counting indicated relatively long surviving cone p

184 ricitabine, and efavirenz) regardless of CD4 cell count (intervention) or according to national guide

185 After adjustment for age, CD4 cell counts, last HIV viral load, antiretroviral therapy

186 and preservation of the cornea, endothelial cell count, lens status, medical and surgical history, a

187 ncreased risk of HFrEF, and time-updated CD4 cell count less than 200 cells/mm3 compared with at leas

188 cell count parameter thresholds: white blood cell count less than 5000/microL, 10% (95% CI, 4% to 16%

189 (aged >/=18 years) living with HIV with CD4 cell count less than or equal to 350 cells per muL who w

190 study to assess the effects of pre-ART CD4+ cell count levels on death, attrition, and death or attr

191 sing aldosterone levels) and reduces T and B cell counts, likely reflecting a redistribution of these

192 for HIV-positive people were obtaining a CD4 cell count, linkage to an HIV clinic, ART initiation, an

193 ency virus-infected patients who had a CD4 T-cell count <100 cells/microL and negative serum cryptoco

194 hronic myelomonocytic leukaemia (white blood cell count <13 000/muL), and had anaemia with or without

195 stratified into myelodysplastic (white blood cell count <13 x 10(9)/L) and proliferative (white blood

196 mL; 5% and 18% vs 2% of person-time with CD4 cell count <200/microL; P < .001 for each comparison).

197 hospitalized HIV-infected patients with CD4 cell counts <350/microL and microbiologically proved tub

198 is) versus non-LTNP-C, who developed CD4(+)T-cells counts <500 cells/mm(3) Both a Spanish study cohor

199 is) versus non-LTNP-C, who developed CD4(+)T-cells counts <500 cells/mm(3) Both a Spanish study cohor

200 a of age (7-12, 13-17, and 18-30 years), CD4 cell count (<200, 200-499, and >/=500/muL), and a combin

201 s who had both short LTL (<Q1) and low CD34+ cell count (<Q1) had the greatest risk of adverse outcom

202 upon ART initiation were compared to CD4+ T-cell count-matched patients without C-IRIS (N = 27).

203 HIV-1 RNA levels in CSF, and lower CD4(+) T-cell counts may reflect disturbances in the immune respo

204 tal of 5,083 (87.8%) having at least one CD4 cell count measure were included from 2005 to 2013.

205 Participants had induced sputum cell counts measured and blood analysed for sex hormones

206 ] copies/mL; P < .001), increased the CD4+ T-cell count (median [IQR], from 461 [332-663] to 687 [533

207 ion day was associated with lower absolute B-cell counts (median [interquartile range], 0.133 [0.093-

208 32 of 362 [8.8%]) and had lower current CD4 cell counts (median, 230 vs 383 cells/microL), lipid lev

209 Differential cell counts, microarray analysis of cell pellets, and SO

210 settings in the near term, point of care CD4 cell counts might have a role in prioritising care and i

211 ll as ethnic differences in peripheral blood cell counts (normal hematopoiesis) in addition to suscep

212 Moreover, cell counts obtained in different areas by the automated

213 5.20 (95% CI, 2.70-10.02) for a white blood cell count of >/=20 000/muL vs <20 000/muL.

214 ores, as were older age and a nadir CD4(+) T-cell count of <200 cells/mm(3).

215 He was found to have an elevated white blood cell count of 12.2 x 10(9)/L (reference range, [3.9-10.3

216 dian age of 39 years (33-45), and median CD4 cell count of 441 cells per mm(3) (294-628).

217 dian age of 12 years, and median white blood cell count of 48.8 x 10(9)/L.

218 ratory investigations revealed a white blood cell count of 6.7 x 10(9), a C-reactive protein level of

219 ot receiving antiretrovirals and had a CD4 T-cell count of greater than 500 cells per muL.

220 .0% (95% CI 5.8-6.2) among people with a CD4 cell count of less than 100 cells per muL, with 278 000

221 a VL of 400 copies/mL or more and with a CD4 cell count of less than 200/microL compared with 7- to 1

222 in ART-naive HIV-positive patients with CD4 cell count of more than 500 cells per muL assigned to im

223 uartile range [IQR], 0.6-1.1), CD4 and CD8 T-cell counts of 565 (IQR, 435-742) cells/microL and 727 (

224 individuals who are naive to ART, with CD4 T-cell counts of more than 500 per muL.

225 eosinophil counts (out of total white blood cell count) of 2% or greater (rate ratio 1.22 [95% CI 1.

226 n significantly correlated with inflammatory cell count on endomyocardial biopsy (r=0.56; P<0.05).

227 between plasma Gal-3 levels and inflammatory cell count on endomyocardial biopsy was observed in pati

228 . late immunotherapy), and a low white blood cell count on the first cerebrospinal examination (odds

229 Anterior chamber cells count on OCT did not differ between inactive uveit

230 nt each: myalgia (one [2%]), increased blast cell count (one [2%]), and general physical health deter

231 nt for latest HIV RNA level, but not for CD4 cell count or cancer risk factors, attenuated the effect

232 ivity, and inflammatory markers (white blood cell count or cytokine level).

233 onger length of stay, and higher white blood cell count or MELD score at discharge.

234 th advanced HIV infection and with a low CD4 cell count or re-present with persistent low CD4 cell co

235 CMV viruria was not associated with mean CD4 cell counts or HIV viral load but was associated with yo

236 for End-Stage Liver Disease and white blood cell count (OR, 4.68; 95% CI, 1.80-12.17; P = .001).

237 ificantly influenced by HIV RNA levels, CD4+ cell counts, or antiretroviral therapy.

238 ing 60 to 100% of the cancer patients with a cell count over the healthy threshold, depending on the

239 tent ( P = .003), and those with a lower CD4 cell count ( P = .036).

240 sociated with: 1) lower multinucleated giant cell count (P = 0.04); 2) lower density of mesenchymal c

241 k of lung cancer was associated with low CD4 cell count (p trend=0.001), low CD4/CD8 ratio (p trend=0

242 counts (P < .05), without affecting CD4(+) T-cell counts (P > .1).

243 n was found between antimicrobial effect and cell counts (P >0.05).

244 were mechanically ventilated exhibited lower cell counts (P < .001, P < .01, respectively).

245 eduction in allergen-specific IL-4-producing cell counts (P < .01).

246 served between activated B-cell and memory T-cell counts (P < .02).

247 hich was driven by higher levels of CD8(+) T-cell counts (P < .05), without affecting CD4(+) T-cell c

248 No complete blood cell count parameter at commonly used or optimal thresho

249 itivities were low for common complete blood cell count parameter thresholds: white blood cell count

250 linical examination findings and white blood cell count parameters compared with a valid reference st

251 te the accuracy of individual complete blood cell count parameters to identify febrile infants with I

252 r bacterial meningitis, using complete blood cell count parameters.

253 and correlated with viral load and CD4(+) T-cell counts/percentages in 93 HIV-1-infected patients su

254 Viable cell counts, proliferation, and apoptosis were determine

255 vel (r = 0.572, P < .001), circulating tumor cell count (r = 0.613, P = .004), and BSI (r = 0.565, P

256 specific antigen level and circulating tumor cell count (r = 0.63 [95% CI: 0.27, 0.83] and r = 0.77 [

257 B-cell/T-cell ratio and nonswitched memory B-cell counts (r = 0.42, P = .03).

258 Daily total phytoplankton cell counts ranged from 346 to 2,012 cells/mL (median, 7

259 rkers and age-associated CD4(+) and CD8(+) T-cell count ratios identified 4 groups of children.

260 erial rate based on the reduction of sessile cell count reached 98.3% after 24-hour treatment.

261 analyses, a low CD34(+) and CD34(+)/CXCR(+) cell count remained independently associated with a diag

262 l counts, and 91 and 91 with HIV and low CD4 cell counts, respectively).

263 MV infection is associated with higher CD8 T-cell counts, resultant lower CD4/CD8 ratios, and increas

264 s in those not infected, irrespective of CD4 cell count, resulting in lower levels of serotype-specif

265 Cell counts revealed a predominance of microalgae in the

266 CD4 T-cell count, RPR titer and syphilis stage did not affect

267 Mammary quarter milk somatic cell count (SCC) and N-acetyl-beta-d-gluconaminidase (NA

268 dance was predictive of higher host T-helper cell counts, suggesting an important link between Lactob

269 Both hormones induced cell proliferation (cell counts), survival (Annexin-PI), viability (WST-1) a

270 e staging with referral laboratory-based CD4 cell count testing is a key barrier to the initiation of

271 ral, and then (1:1) either point-of-care CD4 cell count testing or referral for CD4 testing.

272 multivariable analysis, particularly the CD4 cell count, the HR for immediate-initiation group moved

273 cows in early lactation or with high somatic cell count, the root mean square error of prediction was

274 n, C-reactive protein level, and white blood cell count, this association remained significant (highe

275 d sensing can accurately determine microbial cell counts throughout cellular concentrations typically

276 nformation about the association of age, CD4 cell count, viral load (VL), and antiretroviral (ARV) dr

277 n and 6016 women), the mean (SD) endothelial cell count was 2732 (437) cells/mm2.

278 n and 6016 women), the mean (SD) endothelial cell count was 2732 (437) cells/mm2.

279 At 1 year post-AHCT, median CD4(+) T-cell count was 280.3 (range, 28.8-1148.0); 82.6% had an

280 The probiotic cell count was higher than 6.5 and 7 log colony-forming

281 During follow-up, CD4 cell count was measured on average every 4.0 months and

282 pe MBL; p<0.0001), but the median absolute B-cell count was similar (227 [IQR 152-345] cells per muL

283 tration, a decrease of 4log cycles in viable cell counts was observed at 10h, against four of the fiv

284 ual disease < 0.1%, CSF blast, regardless of cell count, was an independent adverse predictor of outc

285 tion, fluid, appendicoliths, and white blood cell count (WBC) were significantly correlated with the

286 specific antigen level and circulating tumor cell count were assessed by using Spearman correlation (

287 gnificant differences in sex and white blood cell count were found.

288 Older age and baseline CD8 cell count were independent predictors of infection-unre

289 complete metabolic panel, and complete blood cell count were performed at 4 hours after CR.

290 Increased cell counts were consistently found in the saline-treate

291 ects (24% vs 33%, P = .04), whereas CD3(+) T-cell counts were higher (62% vs 52%, P = .05).

292 ional and CD19(+)CD24(-)CD38(-) new memory B-cell counts were higher in patients with AD versus those

293 Circulating CD19(+)CD20(+) B-cell counts were lower in patients with pediatric AD tha

294 to immediate ART or deferral until their CD4 cell counts were lower than 350 cells per muL.

295 Proliferating casein/T-effector cell counts were measured in children with CM-FPIES, chi

296 Differential cell counts were performed on the bronchoalveolar lavage

297 siveness (AHR) measurements and differential cell counts were performed.

298 thy controls (451, P = .0007), whereas CD8 T-cell counts were similar to controls' levels in HIV-posi

299 darone for the population using LC/MS/MS and cell counting with flow cytometry.

300 to 0.12; P = 0.10), and corneal endothelial cell count (WMD, 73.39; 95% CI, -6.28 to 153.07; P = 0.0